Skip to search formSkip to main contentSkip to account menu

TKI 258

Known as: TKI-258, TKI258 
National Institutes of Health

Related topics

Related topics

2 relations
CHIR-258Dovitinib Lactate

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
Successful implementation of a novel trial model: The Signature program.
106 Background: Here we describe 8 ongoing single agent clinical protocols under Novartis’ “Signature” program involving… 
Review
2013
Review
2013
Final results of a multicenter, open-label phase II trial of dovitinib (TKI258) in patients with advanced urothelial carcinoma with either mutated or nonmutated FGFR3.
255 Background: Increased signaling through mutational activation of fibroblast growth factor receptor 3 (FGFR3) contributes to… 
Review
2013
Review
2013
The N 550 K / H Mutations in FGFR 2 Confer Differential Resistance to PD 173074 , Dovitinib , and Ponatinib ATP-Competitive Inhibitors 1
We sought to identify fibroblast growth factor receptor 2 (FGFR2) kinase domain mutations that confer resistance to the pan-FGFR… 
Review
2013
Review
2013
Are tyrosine kinase inhibitors still active in patients with metastatic renal cell carcinoma previously treated with a tyrosine kinase inhibitor and everolimus? Experience of 36 patients treated in…
2012
2012
Molecular characterization of deletions of the long arm of chromosome 5 (del(5q)) in 94 MDS/AML patients
Molecular characterization of deletions of the long arm of chromosome 5 (del(5q)) in 94 MDS/AML patients 
2012
2012
Reduced intensity allogeneic haematopoietic cell transplantation for chronic lymphocytic leukaemia: related donor and umbilical cord allografting
Allogeneic haematopoietic cell transplantation (HCT) for chronic lymphocytic leukaemia (CLL) is increasingly used due to its… 
Review
2011
Review
2011
A phase II study of dovitinib (TKI258), an FGFR- and VEGFR-inhibitor, in patients with advanced or metastatic renal cell cancer (mRCC).
4551 Background: Dovitinib is a potent oral inhibitor of angiogenic factors, including the fibroblast growth factor (FGFR) and… 
Review
2011
Review
2011
A multicenter, open-label phase II trial of dovitinib, a fibroblast growth factor receptor 1 (FGFR1) inhibitor, in FGFR1-amplified and nonamplified metastatic breast cancer (BC).
289 Background: Amplification of the FGFR1 gene occurs in ≈ 10% of BC, correlates with FGFR1 overexpression, and is mainly… 
2010
2010
A phase I/II study of dovitinib (TKI258), a FGFR and VEGFR inhibitor, in patients (pts) with advanced or metastatic renal cell cancer: Phase I results.
3057 Background: TKI258 selectively targets FGFR1-3, in addition to VEGFR, PDGFR and other tyrosine kinases. FGF pathway has been… 
2009
2009
TKI258 (dovitinib lactate) in metastatic renal cell carcinoma (mRCC) patients refractory to approved targeted therapies: A phase I/II dose finding and biomarker study.
3563 Background: TKI258 is a potent receptor tyrosine kinase inhibitor (TKI) that selectively targets VEGFR, PDGFR, FGFR, CSF1R… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)